Please do not adjust margins
ChemComm
Page 4 of 5
COMMUNICATION
Journal Name
molar activity of 16.2 ± 1.22 GBq µmol–1. As with all
reactions, identification of the product was confirmed
using HPLC, demonstrating co-elution with a sample of
unlabelled iomazenil.
7
8
Sutherland, Angew. Chem. Int. Ed.,D2O0I:1130.,105329,/C778C2C90.6211G
T. C. Wilson, G. McSweeney, S. Preshlock, S. Verhoog,
M. Tredwell, T. Cailly and V. Gouverneur, Chem.
Commun., 2016, 52, 13277.
9
P. Zhang, R. Zhuang, Z. Guo, X. Su, X. Chen and X.
Zhang, Chem. Eur. J., 2016, 22, 16783.
N
N
NMe3 NO2
10 Radioiodination of boron derived arenes using
chloramine-T has also been reported: (a) P. C.
Srivastava, A. P. Callahan, E. B. Cunningham and F. F.
Knapp, J. Med. Chem., 1983, 26, 742. (b) L. Yong, M.-
L. Yao, J. F. Green, H. Kelly and G. W. Kabalka, Chem.
Commun., 2010, 46, 2623.
11 A copper mediated non-radioactive iodination of aryl
boronate esters using iodide as the limiting reagent has
been reported: B. M. Partridge and J. F. Hartwig, Org.
Lett., 2013, 15, 140.
CO2Et
CO2Et
p-TsOH.H2O
N
N
[
125I]NaI, MeCN
60 ºC, 2 h
N
N
125I
NH2
O
O
1i
2i
radioactivity yield: 75 ± 10% (n = 2)
radiochemical purity: >99% (n = 2)
molar activity: 16.2 ± 1.22 GBq µmol–1 (n = 2)
Scheme 2 Radiosynthesis of [125I]iomazenil (2i).
12 (a) T. Sandmeyer, Ber. Dtsch. Chem. Ges., 1884, 17,
1633. (b) H. H. Hodgson, Chem. Rev., 1947, 40, 251.
(c) C. Gali, Chem. Rev., 1988, 88, 765.
13 (a) G.-J. Meyer, K. Rössler and G. Stöcklin, J. Am.
Chem. Soc., 1979, 101, 3121. (b) S. M. Moerlein, C. A.
Mathis and Y. Yano, J. Labelled Compd. Radiopharm.,
1986, 33, 1237. (c) D. S. Wilbur, Bioconjugate Chem.,
1992, 3, 433.
In summary, an operationally simple, one-pot two-step
tandem process for the preparation of radioiodine
containing arenes from readily available anilines has
been developed. The use of mild conditions for diazonium
salt formation resulted in a process with broad scope that
is tolerant of a wide range of functional groups and
substitution patterns. In particular, this process allowed
the preparation of a range of important SPECT imaging
14 (a) M. Caldarelli, I. R. Baxendale and S. V. Ley, Green
Chem., 2000, 2, 43. (b) J. Merrington, M. James and M.
Bradley, Chem. Commun., 2002, 140. (c) V. D.
Filimonov, M. Trusova, P. Postnikov, E. A.
Krasnokutskaya, Y. M. Lee, H. Y. Hwang, H. Kim and
K.-W. Chi, Org. Lett., 2008, 10, 3961. (d) M. E. Trusova,
E. A. Krasnokutskaya, P. S. Postnikov, Y. Choi, K.-W.
Chi and V. D. Filimonov, Synthesis, 2011, 2154
15 The radiochemistry nomenclature used in this paper is
in accordance with the new guidelines recommended by
the Society of Radiopharmaceutical Sciences. See:
H. Elsinga, EJNMMI Radiopharmacy and Chemistry,
2017, 2:2.
agents, including
[
[
125I]iomazenil,
[
125I]CNS1261 and
125I]IBOX, as well as the first radiosynthesis of a high
affinity agent of TSPO, that can now be used to study
neuroinflammation. Current studies are investigating the
application of this method for the development of novel
SPECT imaging agents and the use of solid-phase
extraction for more simple and rapid purification.
Financial support from Medical Research Scotland
(studentship to N.L.S.), G.E. Healthcare Ltd and the
University of Glasgow is gratefully acknowledged.
16 See supplementary information for full details on the
synthesis of each amine precursor.
17 For example: (a) S. S. Zoghbi, R. M. Baldwin, J. P.
Seibyl, M. S. Al-Tikriti, Y. Zea-Ponce, M. Laruelle, E. H.
Sybirska, S. W. Woods, A. W. Goddard, R. T. Malison,
R. Zimmerman, D. S. Charney, E. O. Smith, P. B. Hoffer
and R. B. Innis, Nucl. Med. Biol., 1992, 19, 881. (b) K.
Mori, T. Mori, Y. Toda, E. Fujii, M. Miyazaki, M. Harada
and S. Kagami, Brain and Development, 2012, 34, 478.
18 (a) J. Owens, A. A. Tebbutt, A. L. McGregor, K.
Kodama, S. S. Magar, M. E. Perlman, D. J. Robins, G.
J. Durant and J. McCulloch, Nucl. Med. Biol., 2000, 27,
557. (b) R. J. J. Knol, K. De Bruin, B. L. F. Van Eck-
Smit, S. Pimlott, D. J. Wyper and J. Booij, Synapse,
2009, 67, 557.
19 Z.-P. Zhuang, M.-P. Kung, C. Hou, K. Plössl, D.
Skovronsky, T. L. Gur, J. Q. Trojanowski, V. M.-Y. Lee
and H. F. Kung, Nucl. Med. Biol., 2001, 28, 887.
20 B. J. McBride, R. M. Baldwin, J. M. Kerr and J.-L. Wu,
Appl. Radiat. Isot., 1991, 42, 173.
21 A. Blair, L. Stevenson, D. Dewar, S. L. Pimlott and A.
Sutherland, MedChemCommun., 2013, 4, 1461.
22 F. Zmuda, G. Malviya, A. Blair, M. Boyd, A. J.
Chalmers, A. Sutherland and S. L. Pimlott, J. Med.
Chem., 2015, 58, 8683.
Notes and references
1
2
3
(a) S. M. Ametamey, M. Honer and P. A. Schubiger,
Chem. Rev., 2008, 108, 1501. (b) P. W. Miller, N. J.
Long, R. Vilar and A. D. Gee, Angew. Chem. Int. Ed.,
2008, 47, 8998. (c) S. Preshlock, M. Tredwell and V.
Gouverneur, Chem. Rev., 2016, 116, 719.
(a) M. J. Adam and D. S. Wilbur, Chem. Soc. Rev.,
2005, 34, 153. (b) A. Signore, S. J. Mather, G. Piaggio,
G. Malviya and R. A. Dierckx, Chem. Rev., 2010, 110,
3112. (c) S. L. Pimlott and A. Sutherland, Chem. Soc.
Rev., 2011, 40, 149.
(a) R. H. Seevers and R. E. Counsell, Chem. Rev.,
1982, 82, 575. (b) M. M. Khalil, J. L. Tremoleda, T. B.
Bayomy and W. Gsell, Int. J. Mol. Imag., 2011, 2011,
Article ID 796025.
4
5
For example: S. L. Pimlott, L. Stevenson, D. J. Wyper
and A. Sutherland, Nucl. Med. Biol., 2008, 35, 537.
For example: A. G. Horti, A. O. Koren, K. S. Lee, A. G.
Mukhin, D. B. Vaupel, A. S. Kimes, M. Stratton and E.
D. London, Nucl. Med. Biol., 1999, 26, 175.
6
(a) N. L. Sloan and A. Sutherland, Synthesis, 2016, 48,
2969. (b) D. T. Racys, S. A. I. Sharif, S. L. Pimlott and
A. Sutherland, J. Org. Chem., 2016, 81, 772.
4 | J. Name., 2012, 00, 1-3
This journal is © The Royal Society of Chemistry 20xx
Please do not adjust margins